Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Research output: Contribution to journal › Journal article › peer-review
Standard
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes : what is up, what is down? / Nauck, M A; Vardarli, I; Deacon, C F; Holst, Jens Juul; Meier, Joachim.
In: Diabetologia, Vol. 54, No. 1, 2011, p. 10-18.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes
T2 - what is up, what is down?
AU - Nauck, M A
AU - Vardarli, I
AU - Deacon, C F
AU - Holst, Jens Juul
AU - Meier, Joachim
PY - 2011
Y1 - 2011
N2 - The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.
AB - The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a role in the pathophysiology and treatment of type 2 diabetes, assessment of meal-related GLP-1 secretory responses in type 2 diabetic patients vs healthy individuals is of great interest. A common view states that GLP-1 secretion in patients with type 2 diabetes is deficient and that this applies to a lesser degree in individuals with impaired glucose tolerance. Such a deficiency is the rationale for replacing endogenous incretins with GLP-1 receptor agonists or re-normalising active GLP-1 concentrations with dipeptidyl peptidase-4 inhibitors. This review summarises the literature on this topic, including a meta-analysis of published studies on GLP-1 secretion in individuals with and without diabetes after oral glucose and mixed meals. Our analysis does not support the contention of a generalised defect in nutrient-related GLP-1 secretory responses in type 2 diabetes patients. Rather, factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake.
KW - Animals
KW - Diabetes Mellitus, Type 2
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Incretins
KW - Meta-Analysis as Topic
KW - Models, Biological
U2 - 10.1007/s00125-010-1896-4
DO - 10.1007/s00125-010-1896-4
M3 - Journal article
C2 - 20871975
VL - 54
SP - 10
EP - 18
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - 1
ER -
ID: 38474765